QTQing Tang

Qing Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qing Tang has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Sumei Wang

    Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Department of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Chinese Medicine Guangdong Laboratory, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, 111, Dade Road, Guangzhou, Guangdong 510120, China

    10 shared publications
  • Jingjing Wu

    The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China

    6 shared publications
  • Qichun Zhou

    Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Department of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Chinese Medicine Guangdong Laboratory, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, 111, Dade Road, Guangzhou, Guangdong 510120, China

    6 shared publications
  • Swei Sunny Hann

    Laboratory of Tumor Biology, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China

    6 shared publications
  • Wanyin Wu

    Department of Oncology, Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, the Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangzhou University of Chinese Medicine, Guangzhou, China

    6 shared publications
  • Fang Zheng

    Laboratory of Tumor Molecular Biology and Targeted Therapies of TCM, Guangdong Provincial Hospital of Chinese Medicine, No. 111, Dade Road, Guangzhou, Guangdong Province, 510120, China

    4 shared publications

Latest Publications

  • Fuzheng Kang'ai Formula suppresses NSCLC by inducing a functional crosstalk between autophagy and ferroptosis via EZH2/DOT1L/H3K79me2 signaling

    by Qichun Zhou, Gangxing Zhu, Yongchun Zou, Xiaoyan Yu, Mingnan Ye, Wanyin Wu, Jingpeng Huang, Xiaobing Yang, Qing Tang, Sumei Wang


  • Top Cited Papers
    Open Access

    Mechanisms of drug resistance in hepatocellular carcinoma

    by Yongchun Zou, Xinliang Wan, Qichun Zhou, Gangxing Zhu, Shanshan Lin, Qing Tang, Xiaobing Yang, Sumei Wang

    Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, associated with high morbidity and mortality worldwide. Despite advancements in diagnostic methods and systemic treatments, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), the development of drug resistance remains a significant challenge in HCC management. Traditional treatments such as surgical resection and transarterial chemoembolization offer limited efficacy, especially in advanced stages. Although novel therapies like lenvatinib, sorafenib, regorafenib, and ICIs have shown promise, their effectiveness is often hindered by primary and acquired resistance, leading to poor long-term survival outcomes. This review focuses on the molecular mechanisms underlying resistance to targeted therapies and immunotherapies in HCC. Key factors contributing to resistance include alterations in the tumor microenvironment (TME), immune evasion, hypoxia, changes in cellular metabolism, and genetic mutations. Additionally, molecular players such as ferroptosis, autophagy, apoptosis, endoplasmic reticulum stress, ABC transporters, and non-coding RNAs(ncRNAs) are discussed as contributors to drug resistance. Understanding these mechanisms is critical for the development of novel therapeutic strategies aimed at overcoming resistance, improving patient outcomes, and ultimately enhancing survival rates in HCC patients.


  • Open Access

    Polyphyllin I induces ferritinophagy dependent ferroptosis through EZH2 and promotes anti-tumor immunity

    by Mengfei Xu, Xiaoyan Yu, Luyu Jia, Mingnan Ye, Yueyang Zhao, Rui Wang, Qing Tang, Gangxing Zhu, Jicai Chen, Qichun Zhou, et al.


  • Open Access

    Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment

    by Gangxing Zhu, Xinliang Wan, Wanyin Wu, Luyu Jia, Xiaoyan Yu, Handan Mo, Xi Wang, Qichun Zhou, Qing Tang, Sumei Wang

    A variety of factors, such as dietary habits, the external environment, and individual genetic differences, can lead to the development of cancer. While chemotherapy and radiotherapy are commonly used for cancer treatment, drug resistance and side effects are prevalent issues. Therefore, there is an urgent need to find new treatment modalities. Studies have shown that radiotherapy and chemotherapy can lead to a significant increase in apoptotic cells (ACs) within the tumor microenvironment (TME). The process of phagocytosis helps maintain homeostasis by engulfing and removing these ACs from the organism promptly, which is referred to as efferocytosis. However, it has been observed that excessive efferocytosis can promote the formation of an immunosuppressive TME, which is detrimental to tumor therapy. Thus, inhibiting efferocytosis to enhance the formation of an immune microenvironment shows promise as a treatment direction for tumors. As researchers gradually uncover the molecular mechanisms of efferocytosis, various small‐molecule inhibitors and monoclonal antibodies are actively being assessed in clinical trials. Targeting efferocytosis is anticipated to emerge as a promising approach in tumor treatment. In this review, the intricate steps involved in efferocytosis are explored and the current drugs that targeting this process for cancer treatment are outlined.


  • Open Access

    Risk factors for brain metastasis in lung cancer: an umbrella review of systematic reviews and meta-analyses

    by Xinliang Wan, Handan Mo, Jixin Chen, Qichun Zhou, Shenghong Qiu, Yongchun Zou, Wanyin Wu, Qing Tang, Sumei Wang

    Objectives To conduct an umbrella review to extensively evaluate and summarise the evidence regarding the relationship between risk factors and the occurrence of brain metastasis in lung cancer. Design Umbrella review of systematic reviews and meta-analyses. Data sources Four databases (PubMed, EMBASE, Web of Science and Cochrane Library) were searched from inception to 10 November 2024. Eligibility criteria Systematic reviews and meta-analyses that assessed the relationship between risk factors and brain metastasis in lung cancer were included. Only English language studies were considered. Data extraction and synthesis Two authors independently extracted data and assessed the methodological quality and risk of bias of the included studies. Certainty of evidence was evaluated and summarised for each identified risk factor. Results Six systematic reviews/meta-analyses were included. The quality of these studies varied, with most having low or critically low methodological quality. Epidermal growth factor receptor mutations, female gender, lung adenocarcinoma and advanced tumour stage were associated with an increased risk of brain metastasis. Prophylactic cranial irradiation and older age were associated with reduced risk. Conclusions This umbrella review suggests that several risk factors may be associated with brain metastasis in lung cancer, but the overall quality of evidence is low. Future studies with improved methodologies are needed to validate these findings. PROSPERO registration number CRD42023484563


  • Open Access

    Reprogramming of glucose metabolism: The hallmark of malignant transformation and target for advanced diagnostics and treatments

    by Qing Tang, Siqi Wu, Baiming Zhao, Zhanyang Li, Qichun Zhou, Yaya Yu, Xiaobing Yang, Rui Wang, Xi Wang, Wanyin Wu, et al.


  • Open Access

    Fuzheng Kang-Ai decoction increases the sensitivity of Gefitinib via inducing Non-Small Cell Lung Cancer ferroptosis through AMPK/SLC7A11 pathway

    by YueYang Zhao, MengFei Xu, ShuJing Wang, NanXing Zhong, ShengHong Qiu, Qing Tang, QiChun Zhou, YanQing Pang, HuanMei Lin, XiaoBing Yang, et al.

    Background: Fuzheng Kang-Ai decoction (FZKA), which consists of twelve Chinese herbal medicines (CHM), has been extensively used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients. It was reported in our preceding study that the progression-free survival (PFS) could be prolonged and the toxic effect was reduced after the combination of FZKA and Gefitinib (GFTN) comparing to GFTN alone. Recent studies have shown that FZKA could promote ferroptosis in NSCLC cells. Hence, we assumed that FZKA might strengthen the effect of GFTN by regulating cell ferroptosis in NSCLC. Results: First of all, according to our results, FZKA increased the inhibition effect of NSCLC by GFTN in vitro. Next, we found that FZKA increased the sensitivity of GFTN on cell ferroptosis by testing lipid peroxidation and intracellular-free iron. Interestingly, the effect of FZKA on increasing sensitivity of GFTN in NSCLC cells could be reversed by blocking ferroptosis. Additionally, the results demonstrated that the expression of AMPKα was increased and SLC7A11 reduced in the combined treatment group, at both mRNA and protein levels. Notably, the inhibition of AMPKα reversed the effect of FZKA on increasing GFTN sensitivity. Finally, in vivoexperiments validated that FZKA strengthened the effect of GFTN by inducing NSCLC cell ferroptosis. Conclusions: Based on our findings, we conclude that FZKA increases the sensitivity of GFTN via inducing NSCLC ferroptosis through AMPK/SLC7A11 pathway, providing the solid evidences to the treatment of FZKA together with GFTN in NSCLC patients.

  • Open Access

    FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma

    by Qing Tang, Mengfei Xu, Shunqin Long, Yaya Yu, Changju Ma, Rui Wang, Jing Li, Xi Wang, Fang Fang, Ling Han, et al.


  • Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer

    by Qing Tang, Qichun Zhou, Jing Li, Xiaobing Yang, Rui Wang, Xi Wang, Mengfei Xu, Ling Han, Wanyin Wu, Sumei Wang

    Lung cancer is the leading cause of cancer-related deaths worldwide. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) showed great therapeutic efficacy for non-small cell lung cancer (NSCLC) patients. However, acquired resistance severely limits the clinical application and efficacy of EGFR-TKIs. In the current study, we found that solamargine (SM), a natural alkaloid derived from the fruit of Lycium tomato lobelia, has been found to inhibit the progression of NSCLC and enhance the anticancer effect of EGFR-TKIs. In brief, SM significantly inhibited the cell viability of NSCLC cells and enhanced the anticancer effect of gefitinib (GFTN) and erlotinib (ERL). Mechanistically, SM decreased the expression of MALAT1 and induced miR-141-3p, whereas reduced SP1 protein levels. Interestingly, both MALAT1 and Sp1 have classical and conservative binding sites of miR-141-3p in their 3ʹ-UTR regions. Silence of MALAT1 and overexpression of miR-141-3p both decreased the protein expression of Sp1. Subsequently, promoter activity and protein expression of IGFBP1 were upregulated by SM, which was not observed in cells with SP1 overexpression. Moreover, the inhibitory effect of SM on cell growth was significantly blocked by knockdown of IGFBP1 expression. More importantly, the combination of SM and GFTN synergistically inhibited the progression of lung cancer. Similar results were observed in experiments in vivo. Finally, the clinical relevance of MALAT1, Sp1 and IGFBP1 was further validated using bioinformatics analysis. Taken together, we confirmed that SM significantly enhanced the anticancer effect of EGFR-TKIs by regulating the MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway. This study unravels a novel mechanism and suggests a new potential NSCLC-associated therapy.


  • Open Access

    Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP‐TUG1/miR‐4726‐5p/MUC1 pathway

    by Qing Tang, Xiaojuan Li, Yun Chen, Shunqin Long, Yaya Yu, Honghao Sheng, Sumei Wang, Ling Han, Wanyin Wu

    Hepatocellular carcinoma (HCC) is one of the most common primary malignancies. Drug resistance has significantly prevented the clinical application of sorafenib (SF), a first‐line targeted medicine for the treatment of HCC. Solamargine (SM), a natural alkaloid, has shown potential antitumor activity, but studies about antitumor effect of SM are obviously insufficient in HCC. In the present study, we found that SM significantly inhibited the growth of HCC and enhanced the anticancer effect of SF. In brief, SM significantly inhibited the growth of HepG2 and Huh‐7 cells. The combination of SM and SF showed a synergistic antitumor effect. Mechanistically, SM downregulated the expression of long noncoding RNA HOTTIP and TUG1, followed by increasing the expression of miR‐4726‐5p. Moreover, miR‐4726‐5p directly bound to the 3′‐UTR region of MUC1 and decreased the expression of MUC1 protein. Overexpression of MUC1 partially reversed the inhibitory effect of SM on HepG2 and Huh‐7 cells viability, which suggested that MUC1 may be the key target in SM‐induced growth inhibition of HCC. More importantly, the combination of SM and SF synergistically restrained the expression of MUC1 protein. Taken together, our study revealed that SM inhibited the growth of HCC and enhanced the anticancer effect of SF through HOTTIP‐TUG1/miR‐4726‐5p/MUC1 signaling pathway. These findings will provide potential therapeutic targets and strategies for the treatment of HCC.